The U.S. Chamber expressed its discontent regarding the Senate HELP Committee's upcoming hearing, branding its title and purpose as blatantly biased and accusatory against Novo Nordisk.
Senator Bernie Sanders criticized the exorbitant pricing of Ozempic and Wegovy, stating that the American public is frustrated with the high costs of prescription drugs, necessitating accountability from industry leaders.
The Chamber warns that imposing price controls could lead to dire consequences such as reduced research and innovation, increased wait times for patients, and restricted access to medications.
The Chamber condemned the very concept of the hearing, claiming it was set up to vilify Novo Nordisk and that Sanders had predetermined conclusions regarding the company’s pricing strategies.
Collection
[
|
...
]